W.R. Berkley Corp’s NRX Pharmaceuticals NRXP Stock Holding History

W.R. Berkley Corp’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-27,727	Closed	-$2.86M	–	118
2019 Q1	$2.86M	Buy	27,727 +7,452	+37%	+$765K	0.61%	51
2018 Q4	$2.07M	Hold	20,275	–	–	0.45%	52
2018 Q3	$2.03M	Hold	20,275	–	–	0.31%	68
2018 Q2	$2.01M	Hold	20,275	–	–	0.28%	61
2018 Q1	$1.98M	Buy	20,275 +3,451	+21%	+$336K	0.27%	64
2017 Q4	$1.68M	Buy	+16,824	New	+$1.63M	0.18%	69

Other funds holding NRXP

MSU

Mizuho Securities USA New York $4.24B AUM 23.1% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

OAM

Oxford Asset Management Oxford, United Kingdom $232M AUM 31% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

BFM

Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

WCMNY

Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return

AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

KPF

K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return

YCM

Yakira Capital Management Westport, Connecticut $342M AUM 26.97% 1-Year Est. Return

W.R. Berkley Corp's NRXP Position: Q2 2019 in Review

W.R. Berkley Corp sold out of NRX Pharmaceuticals (NRXP) in Q2 2019, closing a stake of 27,727 shares — an estimated $2.86M sold.

W.R. Berkley Corp first reported a position in NRXP in Q4 2017 and held it in 6 quarters. The position peaked at $2.86M in Q1 2019. 17 funds tracked by Wall St. Rank hold NRXP as of Q2 2019.

W.R. Berkley Corp reported no remaining NRX Pharmaceuticals position as of Q2 2019 after selling out during the quarter.
W.R. Berkley Corp sold 27,727 NRX Pharmaceuticals shares in Q2 2019, an estimated $2.86M.
W.R. Berkley Corp first reported a position in NRX Pharmaceuticals in Q4 2017 and held it in 6 quarters.
W.R. Berkley Corp's NRX Pharmaceuticals position peaked at $2.86M in Q1 2019.
17 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q2 2019.

Based on W.R. Berkley Corp's 13F filing for Q2 2019, filed 14 Aug 2019.